Ozempic and Thyroid Cancer: What the Boxed Warning Actually Means (2026)

Ozempic (semaglutide) carries an FDA boxed warning for the risk of thyroid C-cell tumors, and that warning is the source of nearly every "does Ozempic cause thyroid cancer?" search. Here is the accurate, non-alarmist answer: the warning exists because in long-term rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors — but it is not known whether Ozempic causes these tumors in humans, and as of 2026 there is no established causal link between semaglutide and thyroid cancer in people.^[1] Because of the rodent signal, Ozempic is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).^[1] The human safety studies done so far are mixed and not conclusive — some pharmacovigilance analyses raised a possible signal, while a large cohort study found no substantial increase in risk.^[4][5] This article explains what the warning says, where it comes from, what the human evidence actually shows, who must not take the drug, and which symptoms to watch for. It is general educational information, not medical advice — discuss your own thyroid history with your prescriber. For the broader risk profile see Ozempic side effects and the Ozempic drug page.

What the boxed warning actually says

A boxed warning (often called a "black box" warning) is the most serious warning the FDA can require on a prescription drug label. Ozempic's boxed warning is for the risk of thyroid C-cell tumors. C-cells are the cells in the thyroid gland that produce calcitonin; medullary thyroid carcinoma (MTC) is a cancer that arises from those C-cells. The warning has three parts, and it is important to read all three together rather than just the headline.^[1]

• The finding: in two-year carcinogenicity studies in rats and mice, semaglutide caused thyroid C-cell tumors in a way that depended on the dose and the duration of treatment.^[1]
• The key caveat: it is not known whether Ozempic causes thyroid C-cell tumors, including MTC, in humans — the human relevance of the rodent finding has not been established.^[1]
• The action it requires: Ozempic is contraindicated (must not be used) in people with a personal or family history of MTC or with MEN 2, and all patients should be counseled on thyroid-tumor symptoms.^[1]

In other words, the warning does not say "Ozempic causes thyroid cancer." It says a tumor signal was seen in rodents, the human relevance is undetermined, and out of caution the drug is kept away from the small group of people who are already at elevated genetic risk for this specific cancer. The same boxed warning appears on the Wegovy label, because Wegovy is also semaglutide.^[2] The full label-level discussion of Ozempic's risks is summarized in our Ozempic side effects guide.

Where it comes from — the rodent data

The boxed warning traces back to animal carcinogenicity studies, not to cases in people. In long-term studies in rats and mice, GLP-1 receptor agonists — including semaglutide — were found to activate thyroid C-cells, trigger calcitonin release, and drive C-cell proliferation, which over two years produced dose-dependent C-cell hyperplasia and tumors.^[3] The same class effect was first characterized in detail for liraglutide and then carried across the GLP-1 class.

The reason this matters — and the reason the label says the human relevance is unknown — is that rodent thyroid C-cells are not the same as human thyroid C-cells. Rodents have far more C-cells, and those cells express GLP-1 receptors much more densely than human C-cells do, so they are far more responsive to GLP-1 stimulation. A response seen in a rat thyroid does not automatically translate to a human thyroid. That biological gap is exactly why the FDA worded the warning as an undetermined risk rather than an established one: the rodent finding is real and serious enough to warrant a boxed warning and a contraindication, but it cannot be assumed to predict what happens in people.^[1][3]

The human evidence so far

As of 2026, there is no established causal link between semaglutide and thyroid cancer in humans, and the topic remains under active study. The human evidence is best described as mixed and not conclusive — it is genuinely important not to over-state it in either direction.

• A possible signal (the cautionary side). A French nationwide case-control study by Bezin and colleagues (Diabetes Care, 2023) reported a possible increased risk of thyroid cancer, including medullary thyroid cancer, associated with GLP-1 receptor agonist use, particularly after one to three years of treatment.^[4] Observational studies like this can be affected by detection bias (patients on these drugs see clinicians more often and may simply get more thyroid imaging and testing), so the finding raised a flag but did not prove causation.
• No substantial increased risk (the reassuring side). A large Scandinavian cohort study by Pasternak and colleagues (BMJ, 2024), following roughly 145,000 GLP-1 users against an active comparator, found no substantial increased risk of thyroid cancer, with the data effectively ruling out more than a modest increase.^[5] An active-comparator cohort of this size is generally considered stronger evidence than a case-control analysis.
• Ongoing pharmacovigilance. Regulators continue to monitor adverse-event reporting systems for any thyroid-cancer signal. To date these mixed pharmacovigilance findings have not established a causal relationship, and major agencies have not concluded that semaglutide causes thyroid cancer in humans.^[1]

The honest bottom line on human data: thyroid cancer — and especially medullary thyroid carcinoma — is rare, the studies disagree, and the strongest large-cohort evidence to date is reassuring while not being a clean bill of health. That is why the boxed warning and the contraindication remain in place as a precaution even though a human causal link has not been shown.

Who must NOT take Ozempic — the contraindication

The boxed warning translates into a hard contraindication. Ozempic (and Wegovy) must not be used in people who have:^[1][2]

• A personal history of medullary thyroid carcinoma (MTC), or a family history of MTC (for example a parent, sibling, or child who has had it).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — an inherited condition that sharply raises the lifetime risk of medullary thyroid carcinoma.

This is precisely why a legitimate prescriber screens your personal and family thyroid history before starting Ozempic. If you fall into either group above, semaglutide is not an appropriate medication for you, and your clinician would consider a non-GLP-1 option instead. A telehealth source that prescribes semaglutide without asking about thyroid cancer or MEN 2 history is a safety red flag. Note that ordinary, common thyroid conditions — an underactive thyroid (hypothyroidism) on levothyroxine, or benign thyroid nodules — are a different issue and are covered below; they are not the same as the MTC/MEN 2 contraindication.

Symptoms to watch for

The label asks every patient on Ozempic to be aware of the symptoms of a thyroid tumor and to report them to their prescriber if they appear. These symptoms are non-specific (they can have many benign causes), so the point is not to panic but to get them checked rather than ignored:^[1]

• A lump or mass in the neck.
• Trouble swallowing (dysphagia).
• Persistent hoarseness or a change in your voice.
• Shortness of breath that doesn't have another clear explanation.

Most of the time these symptoms turn out to be something other than thyroid cancer, but because of the boxed warning they should be brought to a clinician promptly so they can be evaluated. This is general guidance, not a substitute for your prescriber's instructions.

Thyroid nodules and hypothyroidism vs the boxed-warning concern

A lot of the worry around "Ozempic and thyroid" mixes up three different things. The boxed warning is specifically about C-cell tumors / medullary thyroid carcinoma. That is not the same as having an underactive thyroid or a benign thyroid nodule, which are common and unrelated to the C-cell concern.

• Hypothyroidism (underactive thyroid). This is a common condition usually managed with daily levothyroxine. It is not the contraindication. Having hypothyroidism does not, by itself, mean you cannot take Ozempic — that is a conversation for your prescriber, who will factor in your overall history. Ozempic is not a treatment for hypothyroidism, and it does not "fix" a thyroid hormone problem.
• Benign thyroid nodules. Thyroid nodules are very common and the large majority are benign. Having a benign nodule is different from having medullary thyroid carcinoma or MEN 2. Whether Ozempic is appropriate when you have a known nodule is a decision for your clinician, who may want the nodule characterized first; it is not an automatic disqualifier the way a personal/family MTC or MEN 2 history is.
• Medullary thyroid carcinoma (MTC) / MEN 2. This is the boxed-warning concern and the actual contraindication. Personal or family history here means Ozempic is not used.^[1]

If you have any thyroid condition or a thyroid nodule, the right move is simply to tell your prescriber and let them decide — not to assume you're disqualified, and not to assume it's automatically fine.

Bottom line — talk to your prescriber about your thyroid history

The boxed warning on Ozempic is real and worth taking seriously, but it is widely misread. What it actually establishes is that semaglutide caused thyroid C-cell tumors in rodents, that the human relevance is undetermined, and that the drug is contraindicated in the specific group with a personal or family history of medullary thyroid carcinoma or MEN 2.^[1] As of 2026 there is no established causal link between Ozempic and thyroid cancer in humans, and the human studies are mixed — a possible signal in one analysis, no substantial increase in a larger cohort — with the topic still under study.^[4][5]

The single most important thing you can do is discuss your personal and family thyroid history with your prescriber before starting or continuing semaglutide, and report any neck lump, trouble swallowing, hoarseness, or unexplained shortness of breath. A legitimate provider screens for the contraindications above and counsels you on these symptoms. If you are choosing where to get care under proper medical supervision, compare the best semaglutide providers, or read our reviews of Found and Ro. For the full safety picture beyond the thyroid warning, see Ozempic side effects and the Ozempic drug page. This article is general education, not medical advice — your prescriber manages your care.